Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $12.20, for a total value of $19,947.00. Following the completion of the transaction, the insider owned 8,617 shares in the company, valued at approximately $105,127.40. This trade represents a 15.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Scott Bizily also recently made the following trade(s):

• On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $19,620.00.
• On Tuesday, June 23rd, Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $117,720.00.

4D Molecular Therapeutics Stock Up 1.2%

FDMT opened at $14.72 on Wednesday. 4D Molecular Therapeutics, Inc. has a 1 year low of $5.97 and a 1 year high of $15.04. The firm has a 50 day moving average price of $11.17 and a 200 day moving average price of $9.97. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03. The company has a market cap of $769.56 million, a PE ratio of -5.60 and a beta of 2.73.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The business had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. Sell-side analysts expect that 4D Molecular Therapeutics, Inc. will post -4.09 earnings per share for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of large investors have recently added to or reduced their stakes in FDMT. Persistent Asset Partners Ltd acquired a new stake in shares of 4D Molecular Therapeutics during the second quarter valued at about $1,936,000. Dimensional Fund Advisors LP lifted its stake in shares of 4D Molecular Therapeutics by 77.3% in the first quarter. Dimensional Fund Advisors LP now owns 522,823 shares of the company’s stock worth $4,863,000 after acquiring an additional 227,982 shares in the last quarter. Exome Asset Management LLC acquired a new position in shares of 4D Molecular Therapeutics in the first quarter worth about $1,216,000. Perigon Wealth Management LLC purchased a new position in 4D Molecular Therapeutics in the second quarter valued at about $1,944,000. Finally, Evergreen Quality Fund GP Ltd. purchased a new position in 4D Molecular Therapeutics in the fourth quarter valued at about $7,136,000. 99.27% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting 4D Molecular Therapeutics

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $36 price target, implying substantial upside from recent trading levels. The firm modestly improved its FY2027 EPS forecast to a loss of $4.34 per share from $4.40, while projecting narrowing losses through FY2030. HC Wainwright analyst estimates
• Positive Sentiment: Other analysts remain constructive: Goldman Sachs reiterated a Buy rating with a $32 target, while the broader analyst consensus is Moderate Buy with an average price target of $29.62. 4D Molecular Therapeutics reaches 12-month high
• Positive Sentiment: FDMT recently reached a new 12-month high, trading well above its 50-day and 200-day moving averages. The stock’s elevated volume and momentum may be attracting additional interest, although its high beta indicates significant volatility. 4D Molecular Therapeutics reaches 12-month high
• Neutral Sentiment: Institutional ownership is reported at 99.27%, with new positions from Bank of America, Man Group, Jupiter Topco and other investors. This signals strong institutional interest, though the reported purchase figures may include data-quality anomalies. Institutional ownership and insider trading
• Negative Sentiment: HC Wainwright reduced its FY2028, FY2029 and FY2030 loss estimates slightly, indicating that FDMT is expected to remain unprofitable for several years. The company also recently reported a quarterly loss of $1.04 per share, missing estimates, despite revenue exceeding expectations.
• Negative Sentiment: Insider Scott Bizily sold shares in multiple transactions totaling roughly $39,567 during August and has reduced his direct holdings by 15.95%. While relatively small, the sales could temper investor sentiment. FDMT insider stock sales

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Chardan Capital raised shares of 4D Molecular Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. The Goldman Sachs Group restated a “buy” rating and set a $32.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. Finally, Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.62.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.